Showing 1 - 10 of 10
A study by health economists at the University of York has, for the first time, produced an estimate of the impact on other NHS patients of new and more costly drugs and other treatments. This research suggests a refinement of the way the National Institute for Health and Clinical Excellence...
Persistent link: https://www.econbiz.de/10010857127
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of golimumab (Schering-Plough/Centocor) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of active and progressive psoriatic arthritis (PsA) in patients who have...
Persistent link: https://www.econbiz.de/10009653282
Persistent link: https://www.econbiz.de/10010614392
The National Institute for Health and Clinical Excellence (NICE) is required to consider cost effectiveness when issuing guidance about the use of health technologies within the UK NHS. Cost effectiveness is a means of supporting a system objective of maximizing population health gain from the...
Persistent link: https://www.econbiz.de/10005449021
Persistent link: https://www.econbiz.de/10005449031
The use of decision-analytic modelling for the purpose of health technology assessment (HTA) has increased dramatically in recent years. Several guidelines for best practice have emerged in the literature; however, there is no agreed standard for what constitutes a `good model' or how models...
Persistent link: https://www.econbiz.de/10005449234
Recently, health systems internationally have begun to use cost-effectiveness research as formal inputs into decisions about which interventions and programmes should be funded from collective resources. This process has raised some important methodological questions for this area of research....
Persistent link: https://www.econbiz.de/10005590356
DOI: 10.2165/0019053-200826090-00001
Persistent link: https://www.econbiz.de/10005590362
Background: The use of granulocyte colony-stimulating factor (G-CSF) can enable dose intensification of chemotherapy in small-cell lung cancer (SCLC). However, given its acquisition cost, it is important to assess its cost effectiveness within a resource-constrained health service. Objective: To...
Persistent link: https://www.econbiz.de/10005590493
In a recent leading article in PharmacoEconomics, Nuijten described some methods for incorporating uncertainty into health economic models and for utilising the information on uncertainty regarding the cost effectiveness of a therapy in resource allocation decision-making. His proposals are...
Persistent link: https://www.econbiz.de/10004990337